Examkin

Question

Difficulty: MediumDiagnostic and Screening Test Performance

A pharmaceutical firm is conducting clinical trials for a novel monoclonal antibody targeting severe plaque psoriasis. Prospective trial participants are initially screened using a new genetic biomarker assay to identify those most likely to respond to the therapy. The assay is first implemented in a specialized academic dermatology center where 40%40\% of the patient population possesses the target genetic profile. Six months later, the identical screening assay is rolled out to general community medicine clinics, where the target genetic profile is present in only 5%5\% of the patient population. The assay's threshold for a positive result remains constant across all sites. When evaluating the performance of the biomarker assay in the community medicine clinics compared to the academic dermatology center, which of the following statistical metrics will be greater?

  1. The probability that a patient with a negative test result is truly unresponsive to the therapyAnswer
  2. B
    The probability that a patient with a positive test result is truly responsive to the therapy
  3. C
    The proportion of truly responsive patients who are correctly identified by a positive test result
  4. D
    The proportion of truly unresponsive patients who are correctly identified by a negative test result
  5. E
    The ratio of the positive test rate in responsive patients to the positive test rate in unresponsive patients

Answer

The probability that a patient with a negative test result is truly unresponsive to the therapy
The correct response describes the Negative Predictive Value (NPV) of a test. When a diagnostic assay is applied to a population with a much lower prevalence of the target condition (dropping from 40%40\% to 5%5\%), the pool of truly disease-free individuals grows significantly. Because there are vastly more healthy individuals in the community cohort, the statistical reliability of a negative test result increases, meaning the probability that a patient with a negative result is truly free of the condition (NPV) becomes greater.

Step-by-Step Solution

1
Identify the underlying change in the clinical scenario.
The test is moved from an academic center with a high disease prevalence (40%40\%) to a community setting with a much lower disease prevalence (5%5\%).
Establishing the directional shift in prevalence is required to determine its impact on statistical parameters.
2
Determine which test parameters are affected by prevalence changes.
Intrinsic properties (Sensitivity, Specificity, Likelihood Ratios) remain constant. Extrinsic predictive properties (Positive Predictive Value and Negative Predictive Value) change.
Predictive values depend on the actual proportion of diseased versus healthy individuals in the tested cohort.
3
Calculate the directional shift of the affected parameters.
A decrease in prevalence results in a lower Positive Predictive Value (PPV) and a higher Negative Predictive Value (NPV).
Fewer true cases mean false positives outnumber true positives (lowering PPV), while the massive increase in healthy individuals makes a negative result highly reliable (raising NPV).
4
Map the statistical findings to the descriptive text in the options.
The option describing NPV ('probability that a patient with a negative test result is truly unresponsive') is the metric that will be greater.
USMLE questions often test conceptual understanding by substituting statistical jargon with practical clinical definitions.

Key Concept

While sensitivity and specificity are intrinsic to a diagnostic test and remain constant, predictive values are heavily dependent on disease prevalence. As prevalence decreases, Negative Predictive Value (NPV) increases and Positive Predictive Value (PPV) decreases.
Estimated Time:1m 30s
Rate this question

Topics

Diagnostic and Screening Test Performance

More questions from this topic